4,605.00
+265(+6.11%)
Currency In KRW
Address
Building 142, Korea Seoul National University
Seoul, 08826
Korea, Republic of
Phone
82 2 3285 7861
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
64
First IPO Date
February 19, 2019
| Name | Title | Pay | Year Born |
| Yuil Kang Chang | Chief Executive Officer & Representative Director | 0 | N/A |
| Kim Minsoo | In charge of Finance/IR(Management Support Office) & Director | 0 | N/A |
| Kim Yookyung | Head of GMP Center & MD | 0 | N/A |
Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.